Operator
Good day, and thank you for standing by. Welcome to the Cardiff Oncology Inc. Conference Call. [Operator Instructions] Please be advised that today’s conference is being recorded. I would now like to hand the conference over to your speaker today, Mani Mohindru, Interim CEO. Please go ahead, ma’am.
Mani Mohindru
Interim CEO & Director
Thank you, operator. Good afternoon, everyone. My name is Mani Mohindru, and I’m the interim CEO of Cardiff Oncology. Thank you for joining today’s webinar where we plan to discuss the evolving treatment landscape in first-line RAS-mutated metastatic colorectal cancer or metastatic CRC. We will also discuss the recently shared clinical data for our novel, highly selective PLK1 inhibitor, onvansertib and its potential to improve outcomes for metastatic colorectal cancer patients when combined with the standard of care therapy.
March is a national colorectal cancer awareness month dedicated to increasing understanding of the prevention, detection and treatment of colon and rectal cancers. According to the National Cancer Institute, more than 154,000 patients in the U.S. were diagnosed with colorectal cancer in 2025 and nearly 53,000 died from the disease. Despite decades of research, first-line RAS-mutated metastatic CRC has seen limited progress, underscoring a significant unmet need. On that note, I’m very pleased to be joined by 2 globally recognized leaders in GI oncology, Dr. Heinz-Josef Lenz and Dr. Steve Kopetz (sic) [ Scott Kopetz ]. Dr. Lenz and Dr. Kopetz, thank you both for being here and for joining this discussion.